Science News
from research organizations

Eye disease: Preliminary Findings on Uveitis Drug

Date:
August 22, 2012
Source:
Wake Forest Baptist Medical Center
Summary:
Scientists have presented preliminary findings of a Phase 3 clinical trial on a new drug for the treatment of uveitis, a serious inflammatory condition of the uvea, the middle layer of the eye that provides most of the blood supply to the retina.
Share:
       
FULL STORY

Shree Kurup, M.D., director of research in the ophthalmology department at Wake Forest Baptist Medical Center, will present the preliminary findings of a Phase 3 clinical trial on a new drug for the treatment of uveitis, a serious inflammatory condition of the uvea, the middle layer of the eye that provides most of the blood supply to the retina. T

he findings will be presented at the annual meeting of the American Society of Retinal Specialists in Las Vegas from Aug. 25 to 29.

Kurup will present his findings on Aug. 28. "This is the first new drug that could be approved in 50 years. Currently only steroids are available," he said.

Non-infectious uveitis involving the posterior segment of the eye is a leading cause of vision loss and long-term disability and the fourth leading cause of legal blindness in the industrialized world.


Story Source:

The above post is reprinted from materials provided by Wake Forest Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest Baptist Medical Center. "Eye disease: Preliminary Findings on Uveitis Drug." ScienceDaily. ScienceDaily, 22 August 2012. <www.sciencedaily.com/releases/2012/08/120822100809.htm>.
Wake Forest Baptist Medical Center. (2012, August 22). Eye disease: Preliminary Findings on Uveitis Drug. ScienceDaily. Retrieved July 2, 2015 from www.sciencedaily.com/releases/2012/08/120822100809.htm
Wake Forest Baptist Medical Center. "Eye disease: Preliminary Findings on Uveitis Drug." ScienceDaily. www.sciencedaily.com/releases/2012/08/120822100809.htm (accessed July 2, 2015).

Share This Page: